PubMed Health⌕ Search

Biomedical subjects

J Feliu

Publications and source records attributed to J Feliu.

83 records · Page 5Linked to original sources
PubMed1988

Sequence and secondary structure of the 5' external transcribed spacer of mouse pre-rRNA.

We report the sequence of the 4006-nucleotide 5' external transcribed spacer (5'ETS) of the mouse ribosomal primary transcript. These data complete the sequence of the 13.4-kb mouse rRNA gene, thus providing a mammalian rRNA gene structure, in addition to yeast and Xenopus. The mouse 5'ETS displays a highly biased base content (very high in GC and particularly low in A), closely similar to the other transcribed spacers of the mouse ribosomal gene. This region seems to have accumulated sequence variation relatively rapidly during vertebrate evolution, with the possible insertion in rodents of sequences structurally similar to retroposons. About half the length of the mouse 5'ETS can fold into a giant and highly stable secondary structure, which is probably evolutionarily conserved in mammals and which could play an important role in the higher-order organization of mammalian pre-ribosomes.

Animals↗
PubMed1988

Association of leukemia and pregnancy: clinical and obstetric aspects.

The association of leukemia and pregnancy is not common. We have analyzed the hematologic and obstetric problems occurring in 10 pregnant leukemic patients, 7 with acute leukemia and 3 with chronic myeloid leukemia. One patient died in the fifth month of pregnancy with a nonviable fetus. There was one premature twin birth with both fetuses dead. The other fetuses were viable, although there was one premature birth and three fetuses had below-normal birth weights. No bleeding complications were observed during delivery. Three patients had infections during puerperium. This article discusses the possible influences and relations between leukemia and pregnancy, based on our observations and on data in the literature.

Adolescent↗
PubMedDate not supplied

Phase I study of UFT plus leucovorin in advanced colorectal cancer: a double modulation proposal.

Twenty-six patients with advanced colorectal cancer were treated with UFT and leucovorin (LV). On day 1, patients received LV 500 mg/m2 in IV infusion, followed by 15 mg/12 h for 13 days. On days 1 to 14, patients took oral UFT twice daily. Three cycles were given every 28 days, unless grade III-IV toxicity appeared. The initial dose of UFT (200 mg/day) was increased until 800 mg/day. Dose limiting toxicities were stomatitis, diarrhea and epigastralgia. The maximum tolerated dose of UFT was 390 +/- 10 mg/m2. Three out of 24 evaluable patients achieved a partial response and 1 a complete response with UFT doses of 260 to 390 mg/m2. These results warrant confirmation in phase II studies.

Administration, Oral↗